The impact of the ClearRT ™ upgrade on target motion tracking accuracy in Radixact ® Synchrony ® lung treatments.

Autor: Kong CW; Medical Physics Department, Hong Kong Sanatorium and Hospital, Hong Kong SAR, China., Chiu TL; Medical Physics Department, Hong Kong Sanatorium and Hospital, Hong Kong SAR, China., Cheung CW; Medical Physics Department, Hong Kong Sanatorium and Hospital, Hong Kong SAR, China., Lee TY; Medical Physics Department, Hong Kong Sanatorium and Hospital, Hong Kong SAR, China., Yeung FK; Medical Physics Department, Hong Kong Sanatorium and Hospital, Hong Kong SAR, China., Yu SK; Medical Physics Department, Hong Kong Sanatorium and Hospital, Hong Kong SAR, China.
Jazyk: angličtina
Zdroj: Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology [Rep Pract Oncol Radiother] 2022 Dec 29; Vol. 27 (6), pp. 1106-1113. Date of Electronic Publication: 2022 Dec 29 (Print Publication: 2022).
DOI: 10.5603/RPOR.a2022.0111
Abstrakt: Background: The objective was to investigate the change in segmentation error of Radixact ® Synchrony ® lung treatment after its kV imaging system was upgraded from Generation 1 to Generation 2 in the ClearRT™ installation.
Materials and Methods: Radixact ® Lung Synchrony ® plans were created for the Model 18023 Xsight ® Lung Tracking "XLT" Phantom combined with different lung target inserts with densities of 0.280, 0.500, 0.943 and 1.093 g/cc. After Radixact ® Synchrony ® treatment delivery using the Generation 1 and Generation 2 kV systems according to each plan, the tracking performance of the two kV systems on each density insert was compared by calculating the root mean square (RMS) error (δ RMS ) between the Synchrony-predicted motion in the log file and the known phantom motion and by calculating δ95%, the maximum error within a 95% probability threshold.
Results: The δ RMS and δ95% of Radixact ® Synchrony ® treatment for Gen1 kV systems deteriorated as the density of the target insert decreased, from 1.673 ± 0.064 mm and 3.049 ± 0.089 mm, respectively, for the 1.093 g/cc insert to 8.355 ± 5.873 mm and 15.297 ± 10.470 mm, respectively, for the 0.280 g/cc insert. In contrast, no such trend was observed in the δ RMS or δ95% of Synchrony ® treatment using the Gen2 kV system. The δ RMS and δ95%, respectively, fluctuated slightly from 1.586 to 1.687 mm and from 2.874 to 2.971 mm when different target inserts were tracked by the Gen2 kV system.
Conclusion: With improved image contrast in kV radiographs, the Gen2 kV imaging system can enhance the ability to track targets accurately in Radixact ® Lung Synchrony ® treatment and reduce the segmentation error. Our study showed that lung targets with density values as low as 0.280 cc/g could be tracked correctly in Synchrony treatment with the Gen2 kV imaging system.
Competing Interests: Conflict of interest The authors declare that they have no conflict of interest.
(© 2022 Greater Poland Cancer Centre.)
Databáze: MEDLINE
Externí odkaz: